Department of Thyroid Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China.
Department of Oral-Maxillofacial-Thyroid Oncosurgery, Jilin Cancer Hospital, Changchun, Jilin, China.
Front Endocrinol (Lausanne). 2023 May 9;14:1136120. doi: 10.3389/fendo.2023.1136120. eCollection 2023.
We attempted to examine the clinical characteristics in patients with breast cancer (BC) and thyroid cancer (TC); explore the potential mechanisms of tumorigenesis and progression.
Using the Surveillance, Epidemiology, and End Result Program-9 (SEER-9) database, a retrospective study (1975-2017) was conducted on patients with BC and TC. We identified the common differentially expressed genes involved in BC and TC using the Gene Expression Omnibus database (GEO). Immunohistochemical staining (IHC) was performed to verify the expression of the hit gene in patients with co-occurrence of BC and TC. Using The Cancer Genome Atlas (TCGA) database, the relationship between gene expression and clinicopathological characters was determined. Gene set enrichment analysis (GSEA) was used to identify the pathways enriched in BC and TC.
BC patients had a higher predisposition to develop TC (standardized incidence ratio, SIR: 1.29) and vice-versa (SIR: 1.12). Most of these patients were differentiated thyroid carcinoma (DTC) and hormone receptor (HR) - positive BC. The mRNA expression of COMP (Cartilage oligomeric matrix protein) was significantly overexpressed in BC and TC by analyzing the GEO database. The protein expression of COMP was increased in both BC and TC tissues obtained from the same patients validated by IHC. COMP was correlated with worse OS in BC (stage II-IV) and TC; it was the independent factor for prognosis of BC. GSEA indicated that the estrogen response and epithelial-mesenchymal transition (EMT) pathways were significantly enriched in both TC- and BC- COMP overexpressed groups.
The co-occurrence risk of BC and TC in the same individual is higher than in the general population. Overexpression of COMP could promote oncogenesis and progression in patients with BC and TC through estrogen signaling and EMT pathways.
我们试图研究乳腺癌（BC）和甲状腺癌（TC）患者的临床特征；探索肿瘤发生和进展的潜在机制。
使用监测、流行病学和最终结果计划-9（SEER-9）数据库，对 1975 年至 2017 年期间患有 BC 和 TC 的患者进行回顾性研究。我们使用基因表达综合数据库（GEO）确定 BC 和 TC 中涉及的常见差异表达基因。通过免疫组织化学染色（IHC）验证共同发生 BC 和 TC 的患者中命中基因的表达。使用癌症基因组图谱（TCGA）数据库，确定基因表达与临床病理特征之间的关系。基因集富集分析（GSEA）用于鉴定 BC 和 TC 中富集的途径。
BC 患者发生 TC 的风险更高（标准化发病比，SIR：1.29），反之亦然（SIR：1.12）。这些患者大多数为分化型甲状腺癌（DTC）和激素受体（HR）阳性 BC。通过分析 GEO 数据库，发现 COMP（软骨寡聚基质蛋白）在 BC 和 TC 中的 mRNA 表达明显上调。免疫组织化学验证了来自同一患者的 BC 和 TC 组织中 COMP 蛋白表达增加。COMP 与 BC（II-IV 期）和 TC 的 OS 较差相关；它是 BC 预后的独立因素。GSEA 表明，TC 和 BC-COMP 过表达组中雌激素反应和上皮-间充质转化（EMT）途径明显富集。
同一患者中 BC 和 TC 的共同发生风险高于一般人群。COMP 的过表达可能通过雌激素信号和 EMT 途径促进 BC 和 TC 患者的肿瘤发生和进展。
